戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 he mechanism for its increased production in cutaneous lupus erythematosus.
2 s that closely resembled the pattern seen in cutaneous lupus erythematosus.
3  to be of therapeutic value in patients with cutaneous lupus erythematosus.
4 with adult dermatomyositis and with subacute cutaneous lupus erythematosus.
5 erences between dermatomyositis and subacute cutaneous lupus erythematosus.
6 hibits some features in common with subacute cutaneous lupus erythematosus.
7 r necrosis factor alpha, similar to subacute cutaneous lupus erythematosus.
8 to the accumulation of inflammatory cells in cutaneous lupus erythematosus.
9 d safety of litifilimab for the treatment of cutaneous lupus erythematosus.
10  erythematosus (DLE) is a chronic variant of cutaneous lupus erythematosus, an autoimmune inflammator
11 ly increased prevalence of -308A in subacute cutaneous lupus erythematosus, an extremely photosensiti
12        On dermatologic examination, subacute cutaneous lupus erythematosus and chronic cutaneous lupu
13                                     Subacute cutaneous lupus erythematosus and chronic cutaneous lupu
14 have been important developments in defining cutaneous lupus erythematosus and dermatomyositis.
15 as identified as being a specific marker for cutaneous lupus erythematosus and found to be strongly e
16 ed with the photosensitive disorder subacute cutaneous lupus erythematosus and mediates an exaggerate
17  are produced by most patients with subacute cutaneous lupus erythematosus and neonatal lupus erythem
18 that IFN-kappa may play a pathogenic role in cutaneous lupus erythematosus and serve as a target for
19 morphism) in adult dermatomyositis, subacute cutaneous lupus erythematosus, and discoid lupus, and co
20 thematosus, on human skin samples of chronic cutaneous lupus erythematosus, and on healthy controls,
21 nflammatory skin diseases such as psoriasis, cutaneous lupus erythematosus, and systemic sclerosis.
22 te cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus are distinct.
23 te cutaneous lupus erythematosus and chronic cutaneous lupus erythematosus are represented in the maj
24                            The mechanisms of cutaneous lupus erythematosus are under active investiga
25                                          The cutaneous lupus erythematosus area and severity index ha
26  of skin injury that shares some features of cutaneous lupus erythematosus, blocking i-20S decreased
27 matosus, an extremely photosensitive form of cutaneous lupus erythematosus, but not in discoid lupus
28       Guttate psoriasis, secondary syphilis, cutaneous lupus erythematosus, capillaritis, pityriasis
29                   The immunologic drivers of cutaneous lupus erythematosus (CLE) and its clinical sub
30                      Sunlight (UVB) triggers cutaneous lupus erythematosus (CLE) and systemic lupus t
31                                Patients with cutaneous lupus erythematosus (CLE) experience significa
32                                              Cutaneous lupus erythematosus (CLE) is a complex inflamm
33                                              Cutaneous lupus erythematosus (CLE) is a disfiguring and
34 s (SLE) pathophysiology and are increased in cutaneous lupus erythematosus (CLE) lesions and blood.
35 s been shown to have beneficial effects in a cutaneous lupus erythematosus (CLE) murine model and imp
36 er similar increased ASCVD risk is seen with cutaneous lupus erythematosus (CLE) remains unclear.
37                                Patients with cutaneous lupus erythematosus (CLE) who develop systemic
38    Despite the significant disease burden of cutaneous lupus erythematosus (CLE), there have been no
39                       Fourteen subjects with cutaneous lupus erythematosus (CLE; n = 10), a mimicker
40 in inflammation (grouped under the rubric of cutaneous lupus erythematosus [CLE]).
41 enrolled in the University of Pennsylvania's Cutaneous Lupus Erythematosus Database study.
42 nd validated a measurement instrument (CLASI-Cutaneous Lupus Erythematosus Disease Area and Severity
43 isease severity as codified by the validated Cutaneous Lupus Erythematosus Disease Area and Severity
44 cent change from baseline to 16 weeks in the Cutaneous Lupus Erythematosus Disease Area and Severity
45 in disease activity was determined using the Cutaneous Lupus Erythematosus Disease Area and Severity
46 with DLE, and 5 of 21 subjects with subacute cutaneous lupus erythematosus) had concomitant systemic
47 n reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively s
48                                              Cutaneous lupus erythematosus is a disfiguring and commo
49                                              Cutaneous lupus erythematosus lesional skin microarray d
50                     We show here that active cutaneous lupus erythematosus lesions are highly coloniz
51           Evaluation of discoid and subacute cutaneous lupus erythematosus lesions showed significant
52  antimalarials are the primary treatment for cutaneous lupus erythematosus, not all patients are equa
53 n analysis on human skin samples of subacute cutaneous lupus erythematosus, on human skin samples of
54 ignificantly associated with either subacute cutaneous lupus erythematosus or discoid lupus.
55 viously reported in Caucasians with subacute cutaneous lupus erythematosus (p = 0.016).
56                                              Cutaneous lupus erythematosus patients were grouped acco
57 pheral blood mononuclear cells isolated from cutaneous lupus erythematosus patients, whereas QC and H
58 und to be significantly enhanced in subacute cutaneous lupus erythematosus patients.
59  could also affect antimalarial responses in cutaneous lupus erythematosus patients.
60 d in chronic inflammatory conditions such as cutaneous lupus erythematosus, psoriasis and chronic ecz
61             Analysis of gene expression from cutaneous lupus erythematosus, psoriasis, atopic dermati
62 alopecia areata, Sjogren syndrome, vitiligo, cutaneous lupus erythematosus, psoriasis, lichen planus,
63                                              Cutaneous Lupus Erythematosus Quality of Life (CLEQoL),
64  lupus erythematosus (LE) including subacute cutaneous lupus erythematosus (SCLE) and discoid lupus e
65  Cutaneous neonatal lupus resembles subacute cutaneous lupus erythematosus (SCLE), and photosensitivi
66 agents have been reported to induce subacute cutaneous lupus erythematosus (SCLE).
67 population and cytokine profiles in lesional cutaneous lupus erythematosus skin could affect antimala
68  mechanisms are likely important in subacute cutaneous lupus erythematosus, the cutaneous subset most
69 ted both with presence and refractoriness of cutaneous lupus erythematosus to therapy.
70             Last, in patients suffering from cutaneous lupus erythematosus, topical application of a
71  a phase 2 trial involving participants with cutaneous lupus erythematosus, treatment with litifilima
72 h DLE with that of 21 subjects with subacute cutaneous lupus erythematosus using transcriptomic and h
73 topathologic features resemble those seen in cutaneous lupus erythematosus with a superficial and dee
74 ssigned adults with histologically confirmed cutaneous lupus erythematosus with or without systemic m